May 26, 2017 11:29 AM EDT
R&D

Kite catch­es the in­side track on the last leg of a race to the fin­ish line with No­var­tis on a CAR-T first

John Carroll

Editor & Founder

The race be­tween No­var­tis $NVS and Kite $KITE to win the first FDA ap­proval of a CAR-T for can­cer is now in the fi­nal stretch …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

Re­gen­eron makes $80M obe­si­ty deal with Han­soh

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times